Pharmaceuticals News and Research

RSS

FDA designates Synageva's sebelipase alfa as Breakthrough Therapy for early onset LAL Deficiency

Synageva BioPharma Corp., a biopharmaceutical company developing therapeutic products for rare diseases, today announced that the U.S. Food and Drug Administration granted Breakthrough Therapy designation to sebelipase alfa for the treatment of early onset lysosomal acid lipase deficiency, also known as Wolman disease.

20 May 2013

Patient compliance: an interview with Dr. Bassam Damaj, CEO of Innovus Pharma

A medication’s optimal results are achieved with specific dose levels and times of administration. In order for patients to achieve the maximum benefit from a medication, they have to adhere to the prescribed dose and time of use.

20 May 2013

Takeda, Lundbeck announce presentation of data from four studies that evaluate vortioxetine for MDD

Takeda Pharmaceutical Company Limited and H. Lundbeck A/S today announced that the companies will be presenting new data from four studies that evaluated effectiveness in treating the overall symptoms of depression in patients taking vortioxetine, an investigational agent under review with the U.S. Food and Drug Administration for the treatment of major depressive disorder.

20 May 2013

Shire's scientific data on treatments for psychiatric disorders to be presented at APA meeting

Shire plc, the global specialty biopharmaceutical company, announces that it will present scientific data in 7 poster presentations at the American Psychiatric Association 166th Annual Meeting in San Francisco, May 18-22.

20 May 2013

Impax announces shipment of authorized generic Zomig tablets and orally disintegrating tablets

Impax Laboratories, Inc. today announced that its generics division, Global Pharmaceuticals, commenced shipment of authorized generic Zomig (zolmitriptan) tablets and orally disintegrating tablets, 2.5 mg and 5 mg, in the U.S., as part of a Distribution, License, Development and Supply Agreement with AstraZeneca UK Limited.

20 May 2013

Boehringer Ingelheim to highlight respiratory research work at ATS 2013

Boehringer Ingelheim will contribute to advancing the scientific discussion in respiratory disease at the American Thoracic Society International Conference in Philadelphia, PA, May 17 – 22.

20 May 2013

ElsaLys Biotech announces first round of financing from Transgene and Sofimac Partners

ElsaLys Biotech, which specializes in the development of therapeutic monoclonal antibodies, announces a first round of financing of 2.1M€ from the biopharmaceutical company Transgene and the investment fund Sofimac Partners.

20 May 2013

BioLineRx signs ATM sales agency agreement with Stifel

BioLineRx Ltd., a biopharmaceutical development company, announced today that it has entered into an at-the-market sales agency agreement with Stifel.

18 May 2013

RUCDR Infinite Biologics creates new Genomics Technology Center

RUCDR Infinite Biologics, the world's largest university-based biorepository, has completed an $11.8 million renovation project to create a new Genomics Technology Center, comprising 12,500 square feet of laboratory, office, and storage space on the Busch Campus of Rutgers, The State University of New Jersey.

18 May 2013

Alnylam reports pre-clinical data from ALN-AS1 program for treatment of AIP

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented key pre-clinical proof-of-concept data from its RNAi therapeutic program targeting aminolevulinate synthase-1 (ALAS-1) for the treatment of porphyria including acute intermittent porphyria.

18 May 2013

Boehringer Ingelheim updates HCPs, patients on COMBIVENT RESPIMAT Inhalation Spray

As part of the company's commitment to chronic obstructive pulmonary disease patients, Boehringer Ingelheim Pharmaceuticals, Inc., a leader in respiratory health, is updating healthcare professionals and patients that the transition to COMBIVENT RESPIMAT (ipratropium bromide and albuterol) Inhalation Spray for the maintenance treatment of COPD is nearly complete.

18 May 2013

Great Strides: Walk for cystic fibrosis

Walks in nearly every state this weekend will raise funds to fight cystic fibrosis as part of Great Strides, the Cystic Fibrosis Foundation's largest national fundraising event.

18 May 2013

GfK to deliver major presentation on personalized medicine at PBIRG Annual General Meeting

GfK will deliver a major presentation about patient perspectives' on personalized medicine at the Pharmaceutical Business and Intelligence Research Group Annual General Meeting, taking place May 19 to 22 in Naples, Florida.

17 May 2013

FDA approves Mylan's ANDA for Fenofibrate Tablets

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has shipped Fenofibrate Tablets, 48 mg and 145 mg.

17 May 2013

FDA clears Oramed Pharmaceuticals' IND for ORMD-0801

Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today that the United States Food and Drug Administration has cleared the Company's Investigational New Drug application for ORMD-0801, its oral insulin capsule.

17 May 2013

Galapagos, AbbVie announce extension of GLPG0634 clinical development collaboration

Galapagos NV and AbbVie announced today an extension of their GLPG0634 clinical development collaboration to include Crohn's disease. Galapagos will fund and complete a Phase 2 program in Crohn's disease, which is designed to facilitate rapid progression into Phase 3.

17 May 2013

AACN to host world's largest conference for nurses who care for high acuity, critically ill patients

Emerging trends in patient care combine with advances in healthcare technology as thousands of nurses who care for high acuity and critically ill patients gather in Boston.

17 May 2013

Biostar Pharmaceuticals revenue decreases 23.9% to $12.1 million in first quarter 2013

Biostar Pharmaceuticals, Inc., a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced financial results of the first quarter ended March 31, 2013.

16 May 2013

Bayer HealthCare to present new data on oncology portfolio at ASCO meeting

Bayer HealthCare announced today that new data on the oncology portfolio, including Nexavar (sorafenib) tablets, Stivarga (regorafenib) tablets and the recently U.S. Food and Drug Administration approved product Xofigo (radium Ra 223 dichloride) injection will be presented at the 49th Annual Meeting of the American Society of Clinical Oncology, May 31 – June 4, in Chicago, IL (USA).

16 May 2013

Prostate cancer drug Xofigo gets FDA approval

The U.S. Food and Drug Administration today approved Xofigo (radium Ra 223 dichloride) to treat men with symptomatic late-stage (metastatic) castration-resistant prostate cancer that has spread to bones but not to other organs.

16 May 2013

Pharmaceuticals News and Research

FDA designates Synageva's sebelipase alfa as Breakthrough Therapy for early onset LAL Deficiency

Patient compliance: an interview with Dr. Bassam Damaj, CEO of Innovus Pharma

Takeda, Lundbeck announce presentation of data from four studies that evaluate vortioxetine for MDD

Shire's scientific data on treatments for psychiatric disorders to be presented at APA meeting

Impax announces shipment of authorized generic Zomig tablets and orally disintegrating tablets

Boehringer Ingelheim to highlight respiratory research work at ATS 2013

ElsaLys Biotech announces first round of financing from Transgene and Sofimac Partners

BioLineRx signs ATM sales agency agreement with Stifel

RUCDR Infinite Biologics creates new Genomics Technology Center

Alnylam reports pre-clinical data from ALN-AS1 program for treatment of AIP

Boehringer Ingelheim updates HCPs, patients on COMBIVENT RESPIMAT Inhalation Spray

Great Strides: Walk for cystic fibrosis

GfK to deliver major presentation on personalized medicine at PBIRG Annual General Meeting

FDA approves Mylan's ANDA for Fenofibrate Tablets

FDA clears Oramed Pharmaceuticals' IND for ORMD-0801

Galapagos, AbbVie announce extension of GLPG0634 clinical development collaboration

AACN to host world's largest conference for nurses who care for high acuity, critically ill patients

Biostar Pharmaceuticals revenue decreases 23.9% to $12.1 million in first quarter 2013

Bayer HealthCare to present new data on oncology portfolio at ASCO meeting

Prostate cancer drug Xofigo gets FDA approval

Event guide: World ADC San Diego eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence